bionpad.blogg.se

Furthermore, the WHO has reported that these appraisals are frequently used as international benchmarks. HiPSC: Human induced pluripotent stem cell ICER: Incremental cost–effectiveness ratio QALY: Quality-adjusted life year.Īt present, the analysis of new healthcare technologies in the UK, known as HTAs, is performed by the NICE and provides the basis for most reimbursement decisions in the UK healthcare system. The impact of an improved efficacy and the avoidance of the requirement for immunosuppressive therapy are demonstrated. Sensitivity analysis illustrating an estimate of a prospective incremental cost–effectiveness ratio for a human induced pluripotent stem cell-derived β-cell therapy compared with the NICE threshold (GB£20,000 per quality-adjusted life year), over a 20-year time horizon. HiPSC: Human induced pluripotent stem cell ICER: Incremental cost–effectiveness ratio QALY: Quality-adjusted life year. The impact of the incorporation of profit margins (30, 50 and 70%), the avoidance of the requirement for immunosuppressive therapy and an increase in manufacturing costs (US$200,000) is demonstrated. Sensitivity analysis illustrating an estimate of a prospective incremental cost–effectiveness ratio for a human induced pluripotent stem cell derived β-cell therapy compared with the NICE threshold (GB£20,000 per quality-adjusted life year), over a 20-year time horizon. ICER: Incremental cost–effectiveness ratio QALY: Quality-adjusted life year.

The efficacy of treatment was assumed to be the same for both the maximum and actual cumulative costs. Comparison of the maximum cumulative cost to fall below the NICE threshold (GB£20,000 per quality-adjusted life year) and the actual cumulative cost of allogeneic islet transplantation.

Sensitivity analysis illustrating the incremental cost–effectiveness ratio of allogeneic islet transplantation with the time horizon limited to 5 years, compared with the NICE threshold (GB£20,000 per quality-adjusted life year). The annual cost and QALY data utilized in the present sensitivity analysis were obtained from the corresponding author of the following publication. Incremental cost–effectiveness ratio of allogeneic islet transplantation over a 20-year time horizon, compared with the NICE threshold (GB£20,000 per quality-adjusted life year).